Treatment of hyperproliferative diseases using active vitamin D analogues
First Claim
Patent Images
1. A method of inhibiting hyperproliferation of malignant or neoplastic cells, comprising treating the cells episodically with an antiproliferative amount of an active vitamin D compound which is a hypocalcemic vitamin D compound having a hydrocarbon moiety at the C24 position, with reduced risk of hypercalcemia;
- the cells expressing a vitamin D receptor.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides a method of inhibiting the hyperproliferative cellular activity of neoplasms and other hyperproliferative diseases with an active vitamin D compound utilizing a high dose, episodic treatment protocol.
145 Citations
41 Claims
-
1. A method of inhibiting hyperproliferation of malignant or neoplastic cells, comprising treating the cells episodically with an antiproliferative amount of an active vitamin D compound which is a hypocalcemic vitamin D compound having a hydrocarbon moiety at the C24 position, with reduced risk of hypercalcemia;
- the cells expressing a vitamin D receptor.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- 21. A method of inhibiting hyperproliferation of malignant or neoplastic cells, comprising treating the cells by co-administering an antihyperproliferative amount of an active vitamin D compound and an effective amount of an agent which is an antineoplastic agent, a bone agent, an antihypercalcemic agent or combinations thereof, the cells expressing a vitamin D receptor, the antiproliferative amount of the active vitamin D compound being administered on an episodic basis which is once per week to about once per 12 weeks.
-
29. A method of inhibiting hyperproliferation of cells in a hyperproliferative disease, comprising treating the cells with an antihyperproliferative amount of an active D compound, the cells expressing a vitamin D receptor, the antiproliferative amount of the active vitamin D compound being administered on an episodic basis which is once per week to about once per 12 weeks.
- 33. A pharmaceutical therapy, comprising episodic co-administration of an active vitamin D compound with an antineoplastic agent.
-
34. A pharmaceutical combination, comprising:
-
a) an active vitamin D compound administered episodically;
b) an antineoplastic agent co-administered with the vitamin D compound.
-
Specification